SKVI SKINVISIBLE, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1085277 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.8%
TTM net income YoY-111.2%
TTM EPS YoY—
Revenue 3-yr CAGR1.9%
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin-2,193.7%
Net margin-4,898.2%
FCF margin—
EBITDA margin-2,097.8%
Returns
ROE—
ROA-829.6%
ROIC (approx.)—
Asset turnover0.17x
Leverage & solvency
Liabilities / assets9,592.8%
Debt / equity—
Current ratio0.01x
Interest coverage-0.81x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-759.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6,166 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 |
| Gross profit | $6,166 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 |
| SG&A expense | $112,378 | $112,821 | $125,931 | $114,051 | $105,939 | $136,174 | $139,912 | $198,693 |
| Operating income | -$111,396 | -$112,817 | -$125,938 | -$114,169 | -$106,057 | -$136,237 | -$139,852 | -$198,743 |
| Interest expense | $144,288 | $142,716 | $141,246 | $144,188 | $144,188 | $142,720 | $141,153 | $168,663 |
| Net income | -$255,684 | -$255,533 | -$267,184 | -$258,357 | -$250,245 | -$274,427 | -$281,005 | $314,771 |
| EBITDA | -$106,212 | -$107,821 | -$120,931 | -$109,051 | -$100,939 | -$131,174 | -$134,912 | -$193,693 |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4,370 | $3,959 | $1,798 | $2,620 | $645 | $120 | $13,396 | $10,336 |
| Receivables | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $470 | $5,000 |
| Current assets | $31,462 | $33,301 | $24,390 | $27,531 | $28,469 | $33,102 | $38,305 | $42,028 |
| Intangibles | $84,849 | $90,033 | $95,029 | $100,036 | $105,154 | $110,273 | $111,249 | $116,189 |
| Total assets | $116,311 | $123,334 | $119,419 | $127,567 | $133,623 | $143,375 | $149,554 | $158,217 |
| Current liabilities | $5.79M | $5.54M | $5.28M | $5.02M | $4.77M | $4.53M | $4.26M | $3.66M |
| Total liabilities | $11.16M | $10.91M | $10.65M | $10.39M | $10.14M | $9.90M | $9.63M | $9.38M |
| Shareholders' equity | -$11.04M | -$10.79M | -$10.53M | -$10.26M | -$10.00M | -$9.75M | -$9.48M | -$9.22M |
| Shares outstanding | 5.40M | 5.40M | 5.40M | 5.40M | 5.40M | 5.40M | 5.40M | 5.32M |
| Cash flow statement | ||||||||
| Operating cash flow | -$90,490 | $2,161 | -$822 | $1,975 | $524 | -$9,189 | -$31,720 | -$16,912 |
| Capital expenditure | — | — | — | $0 | -$1 | — | — | $0 |
| Free cash flow | — | — | — | $1,975 | $525 | — | — | -$16,912 |
| Investing cash flow | — | — | — | $0 | $1 | — | — | $0 |
| Financing cash flow | — | — | — | $0 | $0 | $0 | $34,780 | $26,636 |
| Depreciation & amortization | $5,184 | $4,996 | $5,007 | $5,118 | $5,118 | $5,063 | $4,940 | $5,050 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.